Efficacy of smectide combined with metformin in the treatment of obese or overweight T2DM
Objective:To investigate the clinical efficacy of smeglutide combined with metformin in the treatment of obese or overweight type Ⅱ diabetes mellitus(T2DM)and its effect on bone metabolism.Method:92 obese or overweight T2DM patients admitted to our hospital from January 2020 to January 2023 were selected as the study subjects.According to different treatment methods,the patients were divided into a control group(60 cases treated with metformin)and an observation group(64 cases treated with smectide combined with metformin).The blood glucose,blood lipids,bone density(BDM),type I procollagen amino terminal peptide(PINP),calcium(Ca)β Gel linked degradation products(β-CTX levels,BMI,blood uric acid(SUA),and adverse reactions were analyzed.Results:After treatment,fasting blood glucose(FBG),2-hour postprandial blood glucose(2hBG),glycated hemoglobin(HbA1c),total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),systolic blood pressure(SBP),diastolic blood pressure(DBF)β-The levels of CTX and serum uric acid(SUA)were significantly reduced,while the levels of high-density lipoprotein cholesterol(HDL-C)were significantly increased,and the observed group showed more significant changes(P<0.001).After treatment,PINP in the control group significantly increased,while Ca levels in the observation group significantly increased(P<0.05).After treatment,there was no significant change in BMI between the two groups(P>0.05);However,both groups showed a significant decrease in SUA levels(P<0.05).During the treatment period,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Smegglutide can effectively lower blood sugar,regulate blood pressure,lower blood lipids,inhibit bone resorption,promote bone formation,and protect bone metabolism in the treatment of obese or overweight T2DM patients.
SmegglutideType Ⅱ diabetesBone metabolismType I procollagen amino terminal peptideβ Gel linked degradation productsBlood uric acid
NETL
NSTL
万方数据
维普
